Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 17, Issue 5, 2014, Pages 685-695

  Kasper, Siegfried ^a   Iglesias García, Celso ^b,c   Schweizer, Edward ^d   Wilson, Jacquelyn ^e   Dubrava, Sarah ^e   Prieto, Rita ^f   Pitman, Verne W ^e   Knapp, Lloyd ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL VALLE DEL NALÓN   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d Paladin Consulting Group   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f PFIZER INC   (United States)

Author keywords

Discontinuation; generalized anxiety disorder; maintenance treatment; pregabalin; rebound anxiety

Indexed keywords

LORAZEPAM; PREGABALIN; 4 AMINOBUTYRIC ACID; ANXIOLYTIC AGENT;

ADULT; AGED; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; ANXIETY DISORDERS; CLINICAL TRIAL; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898056648     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001557     Document Type: Article

References (35)

1. Allgulander C, Florea I, Huusom AK (2006) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495-505
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn, text revision. Washington, DC: American Psychiatric Association
3. Baldwin D,Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-Analysis. BMJ 342:d1199
4. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2012) An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry 13:510-516
5. Bandelow B et al. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-Traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312
6. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E (1993) A double-blind, placebocontrolled study comparing the efficacy and safety of ipsapirone vs. lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial. J Clin Psychopharmacol 13:429-437
7. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM (2008) Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. Eur Neuropsychopharmacol 18:673-681
8. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008) Long-Term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18-28
9. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240-249
10. Grant BF, Hasin DS, Stinson FS, Dawson DA, Patricia Chou S, June Ruan W, Huang B (2005) Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: Results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res 39:1-9
11. Guy W (1976) ECDEU assessment manual for psychopharmacology (revised). Rockville, MD, USA: U.S. Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
12. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
14. Hoffman DL, Dukes EM, Wittchen HU (2008) Human and economic burden of generalized anxiety disorder. Depress Anxiety 25:72-90
15. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B (2009) Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:87-96
16. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999) Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923
17. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS (2001) The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 43:218-225
18. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627
19. Lieb R, Becker E, Altamura C (2005) The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 15:445-452
20. Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E (1995) Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 wk of treatment for generalized anxiety disorder. Int Clin Psychopharmacol 10:251-256
21. Mitte K, Noack P, Steil R, Hautzinger M (2005) A meta-Analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141-150
22. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771-782
23. National Institute of Health and Care Excellence (NICE) (2011) Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community Care. NICE clinical guideline 113. http://www.nice.org.uk/CG113. Accessed 8 September 2013
24. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M (2003) Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 160:533-540
25. Pfizer Inc. (2009) LYRICA annex I: Summary of product information (EU). London, UK: European Medicines Agency. Available online at http://www.ema. europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/ 000546/WC500046602.pdf. Accessed 11 Sep 2013
26. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID vs. TID dosing. J Clin Psychopharmacol 25:151-158
27. Rickels K, Case WG, Downing RW, Winokur A (1983) Long-Term diazepam therapy and clinical outcome. JAMA 250:767-771
28. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H (1988) Long-Term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45:444-450
29. Rickels K, Schweizer E, Case WG, Greenblatt DJ (1990) Long-Term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 47:899-907
30. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC (2005) Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebocontrolled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022-1030
31. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ (2010) Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 67:1274-1281
32. Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, Spencer MA, Culpepper L, Keller MB (2006) Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 194:91-97
33. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK (2003) Efficacy and tolerability of paroxetine for the long-Term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258
34. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC (2000) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319-328
35. Yonkers KA, Warshaw MG, Massion AO, Keller MB (1996) Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 168:308-313